Class III antiarrhythmic agents
Composition. Active substance: amiodarone.
Preventing recurrence of:
– Life-threatening ventricular tachycardia (Amiodarone-Darnitsa can only be administered in a hospital setting under observation)
– Documented symptomatic and disabling ventricular tachycardia
– Documented supraventricular tachycardia, if the need to prescribe the drug is established in patients with a condition that is resistant to other therapies or with contraindications to other methods of treating ventricular fibrillation
Treatment of supraventricular tachycardia: slowing or reducing atrial fibrillation or flutter.
Amiodarone can be used in patients with ischemic heart disease and/or left ventricular dysfunction (see the Pharmacodynamics Section).
In adults, the drug is taken orally, during or after a meal, without chewing, with a small amount of liquid.
The usual dosing regimen is 3 tablets per day for 8 to 10 days.
In some cases, higher doses can be used for initial treatment (4 to 5 tablets per day), but always for a short period and under ECG monitoring.
The minimum effective dose should be determined; it may vary depending on the patient from 0.5 tablets per day (1 tablet per 2 days) to 2 tablets per day.
The safety and efficacy of amiodarone in children have not been assessed, so using the drug in children is not recommended.